Edition:
United States

Sanofi SA (SASY.PA)

SASY.PA on Paris Stock Exchange

84.39EUR
11:35am EDT
Change (% chg)

€0.58 (+0.69%)
Prev Close
€83.81
Open
€84.08
Day's High
€84.82
Day's Low
€84.08
Volume
1,236,329
Avg. Vol
2,130,521
52-wk High
€92.97
52-wk Low
€67.22

Select another date:

Mon, Oct 16 2017

Regeneron-Sanofi drug succeeds mid-stage study

Regeneron Pharmaceuticals Inc and Sanofi SA said on Monday their drug to treat inflammation in the esophagus, mainly caused by food allergies, met the main goal of a mid-stage study.

CORRECTED-UPDATE 1-Regeneron-Sanofi drug succeeds mid-stage study

Oct 16 Regeneron Pharmaceuticals Inc and Sanofi SA said on Monday their drug to treat inflammation in the esophagus, mainly caused by food allergies, met the main goal of a mid-stage study.

Aimmune teams with Regeneron, Sanofi on peanut allergy drug

Aimmune Therapeutics Inc said on Monday it would collaborate with Regeneron Pharmaceuticals Inc and Sanofi to develop its experimental peanut allergy drug.

Aimmune teams with Regeneron, Sanofi on peanut allergy drug

Oct 16 Aimmune Therapeutics Inc said on Monday it would collaborate with Regeneron Pharmaceuticals Inc and Sanofi to develop its experimental peanut allergy drug.

Regeneron-Sanofi throat infection drug succeeds key study

Oct 16 Regeneron Pharmaceuticals Inc and Sanofi SA said on Monday their drug to treat patients with a rare throat infection met the main goal of a mid-stage study.

BRIEF-Aimmune Therapeutics collaborates to study AR101 with Regeneron and Sanofi’s dupilumab for peanut allergy

* Aimmune Therapeutics announces clinical collaboration to study AR101 with Regeneron and Sanofi’s dupilumab for peanut allergy

BRIEF-Regeneron and Sanofi announce positive phase 2 study results for dupilumab

* REGENERON AND SANOFI ANNOUNCE POSITIVE PHASE 2 STUDY RESULTS FOR DUPILUMAB IN PATIENTS WITH ACTIVE MODERATE-TO-SEVERE EOSINOPHILIC ESOPHAGITIS

Sanofi boosts vaccines business with 170 million euro investment

VAL-DE-REUIL, France Sanofi on Thursday expressed confidence in the growth of its influenza vaccines after committing to invest 170 million euros to expand its manufacturing facility at Val-de-Reuil in north-western France.

UPDATE 1-Sanofi boosts vaccines business with 170 mln euro investment

* Points to risk of over-optimism over universal flu vaccine (Adds quotes, details)

At least six funds interested in Sanofi European generic drugs unit -Le Figaro

PARIS French pharmaceutical group Sanofi is set to start the process to sell its generic drug business in Europe, and at least six funds have expressed interest to investment banks mandated by group, France's Le Figaro newspaper reported.

Select another date: